Skip to main content
TipRanks
Go Ultimate75% OFF

Marker Therapeutics (GX1) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Marker Therapeutics has a market cap or net worth of EUR 13.16M. The enterprise value is EUR 16.47M.

Market Cap
EUR 13.16M
Enterprise Value
EUR 16.47M

Share Statistics

Marker Therapeutics has 16,673,126 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
16,673,126
Owned by Insiders
2.07%
Owned by Institutions
11.03%

Financial Efficiency

Marker Therapeutics’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -76.65%.

Return on Equity (ROE)
-0.72
Return on Assets (ROA)
-0.64
Return on Invested Capital (ROIC)
-76.65%
Return on Capital Employed (ROCE)
-0.77
Revenue Per Employee
0
Profits Per Employee
-2.43M
Employee Count
5
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Marker Therapeutics is -1.77. Marker Therapeutics’s PEG ratio is -0.01.

PE Ratio
-1.77
PS Ratio
11.51
PB Ratio
1.35
Price to FCF
-1.45
Price to Operating Cash Flow
-1.69
PEG Ratio
-0.01

Income Statement

In the last 12 months, Marker Therapeutics had revenue of 0 and earned -12.16M in profits. Earnings per share was -0.79.

Revenue
0
Gross Profit
0
Operating Income
-12.89M
Pretax Income
-12.18M
Net Income
-12.16M
EBITDA
-12.44M
Earnings Per Share (EPS)
-0.79

Cash Flow

In the last 12 months, operating cash flow was -9.76M and capital expenditures -8, giving a free cash flow of -9.76M billion.

Operating Cash Flow
-9.76M
Free Cash Flow
-9.76M
Free Cash Flow per Share
-0.51

Dividends & Yields

Marker Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-70.29%
Earnings Yield
-54.15%

Stock Price Statistics

Beta
1.24
52-Week Price Change
4.07%
50-Day Moving Average
0.84
200-Day Moving Average
1.00
Relative Strength Index (RSI)
42.23
Average Volume (3m)
―

Important Dates

Marker Therapeutics upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Mar 24, 2027
Ex-Dividend Date
―

Financial Position

Marker Therapeutics as a current ratio of 8.39, with Debt / Equity ratio of 0.00%

Current Ratio
8.39
Quick Ratio
8.39
Debt to Market Cap
0.00
Net Debt to EBITDA
1.29
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Marker Therapeutics has paid -15.16K in taxes.

Income Tax
-15.16K
Effective Tax Rate
0.00

Enterprise Valuation

Marker Therapeutics EV to EBITDA ratio is -0.29, with an EV/FCF ratio of -0.26.

EV to Sales
2.07
EV to EBITDA
-0.29
EV to Free Cash Flow
-0.26
EV to Operating Cash Flow
-0.26

Balance Sheet

Marker Therapeutics has EUR 11.33M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 11.33M billion.

Cash & Marketable Securities
EUR 11.33M
Total Debt
EUR 0.00
Net Cash
EUR 11.33M
Net Cash Per Share
EUR 0.68
Tangible Book Value Per Share
EUR 0.63

Margins

Gross margin is -320.83%, with operating margin of -868.95%, and net profit margin of -706.23%.

Gross Margin
-320.83%
Operating Margin
-868.95%
Pretax Margin
-707.46%
Net Profit Margin
-706.23%
EBITDA Margin
-707.46%
EBIT Margin
-707.46%

Analyst Forecast

The average price target for Marker Therapeutics is EUR 8.17, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
EUR 8.17
Price Target Upside
1175.82% Upside
Analyst Consensus
Moderate Buy
Analyst Count
2
Revenue Growth Forecast
-59.58%
EPS Growth Forecast
67.45%